Video Upload Options

References

1. Addissie YA, Kotecha U, Hart RA, Martinez AF, Kruszka P, Muenke M.Craniosynostosis and Noonan syndrome with KRAS mutations: Expanding the phenotypewith a case report and review of the literature. Am J Med Genet A. 2015Nov;167A(11):2657-63. doi: 10.1002/ajmg.a.37259.
2. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005Feb;18 Suppl 2:S19-32. Review.
3. Cancer Genome Atlas Research Network. Comprehensive molecular profiling oflung adenocarcinoma. Nature. 2014 Jul 31;511(7511):543-50. doi:10.1038/nature13385.9;514(7521):262. Rogers, K [corrected to Rodgers, K]. Nature. 2018Jul;559(7715):E12.
4. Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, Digilio C,Palleschi A, Pizzuti A, Grammatico P, Zampino G, Dallapiccola B, Gelb BD,Tartaglia M. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet. 2006 Jul;79(1):129-35.
5. Castagnola P, Giaretti W. Mutant KRAS, chromosomal instability and prognosisin colorectal cancer. Biochim Biophys Acta. 2005 Nov 25;1756(2):115-25.
6. Furukawa T, Sunamura M, Horii A. Molecular mechanisms of pancreaticcarcinogenesis. Cancer Sci. 2006 Jan;97(1):1-7. Review.
7. Gremer L, Merbitz-Zahradnik T, Dvorsky R, Cirstea IC, Kratz CP, Zenker M,Wittinghofer A, Ahmadian MR. Germline KRAS mutations cause aberrant biochemicaland physical properties leading to developmental disorders. Hum Mutat. 2011Jan;32(1):33-43. doi: 10.1002/humu.21377.
8. Karachaliou N, Mayo C, Costa C, Magrí I, Gimenez-Capitan A, Molina-Vila MA,Rosell R. KRAS mutations in lung cancer. Clin Lung Cancer. 2013 May;14(3):205-14.doi: 10.1016/j.cllc.2012.09.007.
9. Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, Aoki Y, MatsubaraY, Arveiler B, Lacombe D, Pasmant E, Parfait B, Baumann C, Héron D, Sigaudy S,Toutain A, Rio M, Goldenberg A, Leheup B, Verloes A, Cavé H.Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPKsignalling pathway: genotype-phenotype relationships and overlap with Costellosyndrome. J Med Genet. 2007 Dec;44(12):763-71.
10. Niihori T, Aoki Y, Narumi Y, Neri G, Cavé H, Verloes A, Okamoto N, HennekamRC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N,Kato K, Kure S, Matsubara Y. Germline KRAS and BRAF mutations incardio-facio-cutaneous syndrome. Nat Genet. 2006 Mar;38(3):294-6.
11. Pérez-Mancera PA, Tuveson DA. Physiological analysis of oncogenic K-ras.Methods Enzymol. 2006;407:676-90.
12. Quezada E, Gripp KW. Costello syndrome and related disorders. Curr OpinPediatr. 2007 Dec;19(6):636-44.
13. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA. Noonan syndrome: clinical features,diagnosis, and management guidelines. Pediatrics. 2010 Oct;126(4):746-59. doi:10.1542/peds.2009-3207.
14. Schubbert S, Bollag G, Lyubynska N, Nguyen H, Kratz CP, Zenker M, Niemeyer CM,Molven A, Shannon K. Biochemical and functional characterization of germ lineKRAS mutations. Mol Cell Biol. 2007 Nov;27(22):7765-70.
15. Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I,Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E,Rauch A, Niemeyer CM, Shannon K, Kratz CP. Germline KRAS mutations cause Noonansyndrome. Nat Genet. 2006 Mar;38(3):331-6.Genet. 2006 May;38(5):598.
16. Tidyman WE, Rauen KA. Mutational and functional analysis in human Ras/MAPkinase genetic syndromes. Methods Mol Biol. 2010;661:433-47. doi:10.1007/978-1-60761-795-2_27.
17. Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R, KorinthenbergR, Kreiss-Nachtsheim M, Meinecke P, Morlot S, Mundlos S, Quante AS, Raskin S,Schnabel D, Wehner LE, Kratz CP, Horn D, Kutsche K. Expansion of the genotypicand phenotypic spectrum in patients with KRAS germline mutations. J Med Genet.2007 Feb;44(2):131-5.